3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Polycystic Ovary Syndrome
11
Solid Tumors
1
Shock, Septic
1
Neoplasms
1
Metabolic Syndrome
1
Menstruation Disturbances
1
Insulin Resistance
1
Infertility, Female
1
Hodgkin Disease
1
Cardiovascular Diseases
1
Interventions
Cyclophosphamide
193
fludarabine phosphate
121
Peripheral Blood Stem Cell Transplantation
106
Etoposide
106
Mycophenolic Acid
94
Filgrastim
91
Doxorubicin
85
Whole-Body Irradiation
83
Tacrolimus
80
Melphalan
78
Brentuximab Vedotin
77
Busulfan
74
Radiotherapy
73
fludarabine
67
Cyclosporine
67
Vinblastine
65
Rituximab
60
Dacarbazine
56
Granulocyte Colony-Stimulating Factor
53
Gemcitabine
52
Antilymphocyte Serum
51
Bleomycin
50
Nivolumab
47
Methotrexate
47
Vincristine
46
Prednisone
45
Cytarabine
43
pembrolizumab
36
Carmustine
36
Bendamustine Hydrochloride
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hodgkin Disease
×
Contraceptives, Oral
×
Clear all
NCT01014507
2012-06-25
PROFE
University of Cologne
Phase 2
Completed
60 enrolled